GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - C4 THERAPEUTICS INC

Financial Performance:

• The transcript contains no specific financial metrics (revenue, earnings, cash flow, debt) or guidance, consistent with C4 Therapeutics being a clinical-stage biopharmaceutical company currently in development phases.

Guidance and Future Outlook:

• Momentum Trial: Expected to complete enrollment in Q1 2027, with initial investigator-assessed data anticipated in the second half of 2027; final independent data and potential accelerated approval filing targeted for 2028 or later.
• Combination Trial (L-renalitinib + Simcitamide): Data expected mid-2027 from all evaluated cohorts.
• New Combinations: Phase 1b studies for Dara-carfilzomib combination planned to begin in 2026 to establish dosing safety and schedules.
• Regulatory Strategy: Aiming for accelerated approval for late-line monotherapy in 2028 based on safety, efficacy, and duration of response; potential to convert to full approval and utilize MRD-negative CR as a pre-defined endpoint for Phase 3 registration.

Business Segments and Product Lines:

• Simcitamide: A cereblon-modulating protein degrader targeting IKZF1 and IKZF3 with a differentiated pharmacology profile (longer half-life, lower protein binding, 14 days on/14 days off dosing).
• Clinical Data: First-in-human study (72 patients + DEX) showed 53% Overall Response Rate (ORR) at RP2D (100 µg), 40% at 75 µg, and 36% across all dose levels in a heavily pre-treated population (75% prior CAR-T or BiTE exposure).
• Safety Profile: Demonstrated the lowest rate of Grade 4 neutropenia and G-CSF use in the class; minimal dose reductions or delays; cleared for safety at 75 µg in combination with L-renalitinib and currently escalating/expanding at 100 µg.
• Pipeline Expansion: Platform focus shifting toward inflammation, neuroinflammation, and neurodegeneration; exploring novel targets but none disclosed yet; potential for non-equity dilutive capital via collaborations (e.g., past Roche deal).

Market and Competitive Landscape:

• Therapeutic Shift: Market moving immune-based strategies (BiTEs, CAR-T) earlier into second line, driven by efficacy and safety improvements (e.g., Pfizer's L-renalitinib data, ASCO guideline updates).
• Differentiation: Simcitamide positioned to offer the efficacy of mezigdomide with the safety of iberdomide; unique dual mechanism (anti-proliferative + immune cell expansion).
• Competitive Positioning: Uniquely pursuing a regulatory IMiD-BiTE combination study; competitors (e.g., Bristol Myers Squibb) are focusing on replacing existing IMiDs, whereas C4 aims to augment immune therapies to improve depth of response (MRD-negative CR) and durability.
• Market Need: High demand for simple, all-oral regimens in the community setting for refractory myeloma patients.

Risks and Challenges:

• Efficacy Bar: Accelerated approval requires an efficacy signal (targeting ≥40% ORR) that exceeds the historical 25% response rate associated with off-label line usage in refractory settings.
• Competitive Landscape: Intense competition in the myeloma space with rapid migration of BiTEs and CAR-Ts to earlier lines; must prove superiority or distinct value over existing standards.
• Clinical Execution: Risk that independent response criteria may differ slightly from investigator assessments, though management expects them to mirror closely.
• Development Scope: Dependence on successful Phase 3 trials to secure full approval if accelerated approval is not achieved in late-line settings.

Management Commentary and Tone:

• Confidence: Management expressed high confidence in the "proof-of-concept" safety and efficacy data, describing the signal as the most robust in the class.
• Strategic Alignment: Strong belief that the market evolution (shifting BiTEs to second line) validates their development strategy and that no other competitor is currently pursuing a regulatory IMiD-BiTE combination.
• Operational Execution: Highlighted successful expansion of the clinical footprint from 13 US centers to 60 sites globally (UK/Western Europe) without changing trial eligibility.
• Tone: Optimistic and data-driven, emphasizing the "best-in-class" potential of Simcitamide's safety and dosing flexibility.

Analyst Questions and Answers:

• Dose Selection: Management clarified that POP-PK models show a weak correlation between higher exposure and neutropenia risk, supporting the use of higher doses (100 µg) for potency while maintaining safety; 75 µg cleared in combination and 100 µg being escalated.
• Late-Line vs. Combination: Explained that the 100 µg dose is for late-line monotherapy, while 75 µg (escalating to 100) is for combinations; this differs from competitors who had to reduce doses significantly (e.g., to 0.6 or 0.3) in similar studies.
• Approval Strategy: Discussed the "efficacy bar" for accelerated approval, noting that drugs will be judged against contemporaneous peers rather than historical CAR-T benchmarks, with a focus on safety and lack of dose modifications.
• Platform Value: Reiterated the platform's role in generating non-equity capital and expanding into neurodegenerative indications, though specific targets remain confidential.
• Partnerships: Stated current focus is on advancing Simcitamide internally but remain open to collaborations if they add value.

Other Key Points:

• Simcitamide is described as a "best-in-class" candidate capable of driving higher quality responses (MRD-negative CR) and faster responses when combined with BiTEs.
• The company's strategy explicitly aims to "rebuild" on the success of early data to support Phase 3 trials that map to MRD-negative CR rates of at least 40%.
• Management highlighted the importance of the 14-day off dosing schedule in enabling combination therapies without compounding neutropenia issues.
• Upcoming focus includes data from the MELT-MM study, ASCO guideline updates, and ELRA trial data to further validate the second-line strategy.